Fig 1: miR‐363‐3p directly inhibits the expression of PTPRC in T‐ALL cell lines. (A) Dual‐Luciferase Reporter Assay for detection of interaction between miR‐363‐3p and full‐length PTPRC 3′UTR or 3′UTR fragment containing predicted miRNA binding site (at the positions 828–834 in the 3′UTR flanked by 30 bp on each site). The graphs present the decrease of relative luciferase activity in the presence of miRNA overexpression vector in reference to empty vector. This interaction was diminished upon introducing mutations within the predicted 7mer‐A1 miR binding site. Below the graph, the predicted interaction site is shown, with indication of nucleotides mutated in rescue experiment. WT—wild‐type sequence; MUT—sequence with mutations introduced within miRNA binding site in 3′UTR; *p < 0.05; ns—not significant. (B, C) Western blot evaluation of PTPRC protein level in DND‐41 (B) and ALL‐SIL (C) upon miR‐363‐3p inhibition (miRZip miR‐363‐3p) as compared to scrambled control (miRZip Scr) in reference to Tubulin Beta Chain (TUBB) as loading control. The graphs present the mean normalized PTPRC protein level from three biological replicates. **p < 0.01.
Supplier Page from Abcam for Anti-beta Tubulin antibody [1E1-E8-H4] - Microtubule Marker